Filing Details

Accession Number:
0001415889-24-016341
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-06-11 16:00:07
Reporting Period:
2024-06-10
Accepted Time:
2024-06-11 16:00:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
59478 Eli Lilly & Co LLY Pharmaceutical Preparations (2834) 350470950
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
316011 Lilly Endowment Inc 2801 North Meridian Street
Indianapolis IN 46208-0068
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-06-10 2,300 $851.69 97,867,020 No 4 S Direct
Common Stock Disposition 2024-06-10 400 $852.36 97,866,620 No 4 S Direct
Common Stock Disposition 2024-06-10 2,313 $854.21 97,864,307 No 4 S Direct
Common Stock Disposition 2024-06-10 3,837 $855.56 97,860,470 No 4 S Direct
Common Stock Disposition 2024-06-10 6,267 $856.67 97,854,203 No 4 S Direct
Common Stock Disposition 2024-06-10 5,879 $857.67 97,848,324 No 4 S Direct
Common Stock Disposition 2024-06-10 8,835 $858.72 97,839,489 No 4 S Direct
Common Stock Disposition 2024-06-10 9,001 $859.49 97,830,488 No 4 S Direct
Common Stock Disposition 2024-06-10 8,374 $860.71 97,822,114 No 4 S Direct
Common Stock Disposition 2024-06-10 954 $861.44 97,821,160 No 4 S Direct
Common Stock Disposition 2024-06-10 3,600 $862.83 97,817,560 No 4 S Direct
Common Stock Disposition 2024-06-10 759 $863.81 97,816,801 No 4 S Direct
Common Stock Disposition 2024-06-10 13,415 $865.06 97,803,386 No 4 S Direct
Common Stock Disposition 2024-06-10 1,780 $865.89 97,801,606 No 4 S Direct
Common Stock Disposition 2024-06-10 3,117 $867.03 97,798,489 No 4 S Direct
Common Stock Disposition 2024-06-10 2,600 $868.21 97,795,889 No 4 S Direct
Common Stock Disposition 2024-06-10 1,500 $869.22 97,794,389 No 4 S Direct
Common Stock Disposition 2024-06-10 579 $870.13 97,793,810 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $851.19 to $852.09, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), and (17) to this Form 4.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $853.98 to $854.71, inclusive.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $855.00 to $855.97, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $856.11 to $857.10, inclusive.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $857.11 to $858.10, inclusive.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $858.12 to $859.11, inclusive.
  7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $859.14 to $860.13, inclusive.
  8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $860.15 to $861.14, inclusive.
  9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $861.19 to $861.68, inclusive.
  10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.26 to $863.23, inclusive.
  11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $863.3625 to $864.3128, inclusive.
  12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $864.4721 to $865.40, inclusive.
  13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $865.5651 to $866.14, inclusive.
  14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $866.69 to $867.37, inclusive.
  15. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $867.72 to $868.6802, inclusive.
  16. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $868.7528 to $869.748, inclusive.
  17. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $869.7693 to $870.74, inclusive.